17 research outputs found
Bicarbonate Alters Bacterial Susceptibility to Antibiotics by Targeting the Proton Motive Force
The
antibacterial properties of sodium bicarbonate have been known for
years, yet the molecular understanding of its mechanism of action
is still lacking. Utilizing chemicalāchemical combinations,
we first explored the effect of bicarbonate on the activity of conventional
antibiotics to infer on the mechanism. Remarkably, the activity of
8 classes of antibiotics differed in the presence of this ubiquitous
buffer. These interactions and a study of mechanism of action revealed
that, at physiological concentrations, bicarbonate is a selective
dissipater of the pH gradient of the proton motive force across the
cytoplasmic membrane of both Gram-negative and Gram-positive bacteria.
Further, while components that make up innate immunity have been extensively
studied, a link to bicarbonate, the dominant buffer in the extracellular
fluid, has never been made. Here, we also explored the effects of
bicarbonate on components of innate immunity. Although the immune
response and the buffering system have distinct functions in the body,
we posit there is interplay between these, as the antimicrobial properties
of several components of innate immunity were enhanced by a physiological
concentration of bicarbonate. Our findings implicate bicarbonate as
an overlooked potentiator of host immunity in the defense against
pathogens. Overall, the unique mechanism of action of bicarbonate
has far-reaching and predictable effects on the activity of innate
immune components and antibiotics. We conclude that bicarbonate has
remarkable power as an antibiotic adjuvant and suggest that there
is great potential to exploit this activity in the discovery and development
of new antibacterial drugs by leveraging testing paradigms that better
reflect the physiological concentration of bicarbonate
Entrapment of Living Bacterial Cells in Low-Concentration Silica Materials Preserves Cell Division and Promoter Regulation
The entrapment of
bacterial cells within inorganic silica materials
was reported almost 20 years ago. However, almost all studies to date
have shown that these entrapped cells are unable to divide and thus
should be expected to have reduced promoter activity. In view of the
importance of bacteria as model systems for both fundamental and applied
biological studies, it is crucial that immobilized cells retain solutionlike
properties, including the ability to divide and display normal promoter
activity. Herein we report on a method to immobilize bacterial cells
within low-density inorganic silica-based materials, where the cells
retain both cell division and promoter activity. Solāgel processing
was used to entrap Escherichia coli cells carrying a variety of green fluorescent protein-linked promoters
into sodium silicate-derived materials that were formed in microwell
plates. Using a series of assays, we were able to demonstrate that
(1) the entrapped cells can divide within the pores of the silica
matrix, (2) cellular pathways are regulated in a similar manner in
both solution and the solāgel-derived materials, and (3) promoters
in entrapped cells can be specifically induced with small molecules
(e.g., antimicrobial compounds) in a concentration-dependent manner
to allow assessment of both potency and mode of action. This solid-phase
assay system was tested using multiple antimicrobial pathways and
should enable the development of solid-phase assays for the discovery
of new small molecules that are active against bacteria
Exploiting the Sensitivity of Nutrient Transporter Deletion Strains in Discovery of Natural Product Antimetabolites
Actinomycete
secondary metabolites are a renowned source of antibacterial chemical
scaffolds. Herein, we present a target-specific approach that increases
the detection of antimetabolites from natural sources by screening
actinomycete-derived extracts against nutrient transporter deletion
strains. On the basis of the growth rescue patterns of a collection
of 22 <i>Escherichia coli</i> (<i>E. coli</i>)
auxotrophic deletion strains representative of the major nutrient
biosynthetic pathways, we demonstrate that antimetabolite detection
from actinomycete-derived extracts prepared using traditional extraction
platforms is masked by nutrient supplementation. In particular, we
find poor sensitivity for the detection of antimetabolites targeting
vitamin biosynthesis. To circumvent this and as a proof of principle,
we exploit the differential activity of actinomycete extracts against <i>E. coli ĪyigM</i>, a biotin transporter deletion strain
versus wildtype <i>E. coli</i>. We achieve more than a 100-fold
increase in antimetabolite sensitivity using this method and demonstrate
a successful bioassay-guided purification of the known biotin antimetabolite,
amiclenomycin. Our findings provide a unique solution to uncover the
full potential of naturally derived antibiotics
MICs, MBCs and MBICs for the top 15 compounds tested against ten Bcc strains<sup>a</sup>.
<p><sup>a</sup> The strains tested were <i>B</i>. <i>cepacia</i> CEP509, <i>B</i>. <i>multivorans</i> C5393, <i>B</i>. <i>cenocepacia</i> J2315, <i>B</i>. <i>cepacia</i> C7322, <i>B</i>. <i>vietnamiensis</i> PC259, <i>B</i>. <i>cepacia</i> CEP021, <i>B</i>. <i>ambifaria</i> CEP0996, <i>B</i>. <i>anthina</i> AU1293, <i>B</i>. <i>pyrrocinia</i> C1469 and <i>B</i>. <i>contaminans</i> FFH-2055.</p><p>MICs, MBCs and MBICs for the top 15 compounds tested against ten Bcc strains<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0128587#t002fn001" target="_blank"><sup>a</sup></a>.</p
A Pipeline for Screening Small Molecules with Growth Inhibitory Activity against <i>Burkholderia cenocepacia</i>
<div><p>Infections with the bacteria <i>Burkholderia cepacia</i> complex (Bcc) are very difficult to eradicate in cystic fibrosis patients due the intrinsic resistance of Bcc to most available antibiotics and the emergence of multiple antibiotic resistant strains during antibiotic treatment. In this work, we used a whole-cell based assay to screen a diverse collection of small molecules for growth inhibitors of a relevant strain of Bcc, <i>B</i>. <i>cenocepacia</i> K56-2. The primary screen used bacterial growth in 96-well plate format and identified 206 primary actives among 30,259 compounds. From 100 compounds with no previous record of antibacterial activity secondary screening and data mining selected a total of Bce bioactives that were further analyzed. An experimental pipeline, evaluating in vitro antibacterial and antibiofilm activity, toxicity and in vivo antibacterial activity using <i>C</i>. <i>elegans</i> was used for prioritizing compounds with better chances to be further investigated as potential Bcc antibacterial drugs. This high throughput screen, along with the in vitro and in vivo analysis highlights the utility of this experimental method to quickly identify bioactives as a starting point of antibacterial drug discovery.</p></div
High throughput screening and compound prioritization process.
<p>Steps are shown as arrows with the name of the step to the left and the selection method to the right.</p
<i>C</i>. <i>elegans</i> rescue assays. <i>C</i>. <i>elegans</i> was allowed to feed on <i>B</i>. <i>cenocepacia</i> K56-2 and OP50 for 16 hours.
<p>The <i>B</i>. <i>cenocepacia</i> infected and OP50-fed worms were subsequently treated with (A) Trimethoprim (TP), Tetracycline (Tet), Meropenem (Mero), Chloramphenicol (Chl) and observed for 6 days every 24 hours and were compared to the non-treated (No Antibiotic) worms for survival. p < 0.0001 for all compounds. (B) The worms were treated with MAC-0013209, (p = 0.2503) with MAC-0151023 and MAC-0036650 at their respective MIC (128 Ī¼g/mL, 32 Ī¼g/mL and 16 Ī¼g/mL); p< 0.0001 for both MAC-0151023 and MAC-0036650 compounds. Trimethoprim was used as a control. p < 0.0001 for all concentrations.</p
Survival <sub>100</sub> (Surv<sub>100</sub>) assay, and the Surv<sub>100</sub>/MIC ratio determination.
<p>(A) The Surv<sub>100</sub> assay was conducted in a 96-well format, where each compound was serially diluted along the rows from its highest soluble concentration or the MIC. The last well for each compound was used as a DMSO control. Approximately, 5 to 10 OP50-fed worms were added to the wells containing LKM for a total assay volume of 100 Ī¼l. The number of worms was counted and recorded for each concentration on day 0 and again 24 hours later. Percent survival was determined for each concentration. The Surv100/MIC ratio was calculated. The compounds, which demonstrated a ratio of 1 and greater, were used in the in vivo antibiotic activity. (B) Photograph of the worms from the assay illustrating the difference between 0% survival and 100% survival.</p
Zinc Chelation by a Small-Molecule Adjuvant Potentiates Meropenem Activity in Vivo against NDM-1-Producing Klebsiella pneumoniae
The
widespread emergence of antibiotic drug resistance has resulted
in a worldwide healthcare crisis. In particular, the extensive use
of Ī²-lactams, a highly effective class of antibiotics, has been
a driver for pervasive Ī²-lactam resistance. Among the most important
resistance determinants are the metallo-Ī²-lactamases (MBL),
which are zinc-requiring enzymes that inactivate nearly all classes
of Ī²-lactams, including the last-resort carbapenem antibiotics.
The urgent need for new compounds targeting MBL resistance mechanisms
has been widely acknowledged; however, the development of certain
types of compoundsīønamely metal chelatorsīøis actively
avoided due to host toxicity concerns. The work herein reports the
identification of a series of zinc-selective spiro-indoline-thiadiazole
analogues that, in vitro, potentiate Ī²-lactam antibiotics against
an MBL-carrying pathogen by withholding zinc availability. This study
demonstrates the ability of one such analogue to inhibit NDM-1 in
vitro and, using a mouse model of infection, shows that combination
treatment of the respective analogue with meropenem results in a significant
decrease in bacterial burden in contrast to animals that received
antibiotic treatment alone. These results support the therapeutic potential
of these chelators in overcoming antibiotic resistance
Inhibition of WTA Synthesis Blocks the Cooperative Action of PBPs and Sensitizes MRSA to Ī²āLactams
Rising drug resistance is limiting treatment options
for infections
by methicillin-resistant <i>Staphylococcus aureus</i> (MRSA).
Herein we provide new evidence that wall teichoic acid (WTA) biogenesis
is a remarkable antibacterial target with the capacity to destabilize
the cooperative action of penicillin-binding proteins (PBPs) that
underlie Ī²-lactam resistance in MRSA. Deletion of gene <i>tarO</i>, encoding the first step of WTA synthesis, resulted
in the restoration of sensitivity of MRSA to a unique profile of Ī²-lactam
antibiotics with a known selectivity for penicillin binding protein
2 (PBP2). Of these, cefuroxime was used as a probe to screen for previously
approved drugs with a cryptic capacity to potentiate its activity
against MRSA. Ticlopidine, the antiplatelet drug Ticlid, strongly
potentiated cefuroxime, and this synergy was abolished in strains
lacking <i>tarO</i>. The combination was also effective
in a <i>Galleria mellonella</i> model of infection. Using
both genetic and biochemical strategies, we determined the molecular
target of ticlopidine as the <i>N-</i>acetylglucosamine-1-phosphate
transferase encoded in gene <i>tarO</i> and provide evidence
that WTA biogenesis represents an Achilles heel supporting the cooperative
function of PBP2 and PBP4 in creating highly cross-linked muropeptides
in the peptidoglycan of <i>S. aureus</i>. This approach
represents a new paradigm to tackle MRSA infection